department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Brynovin · pharmadog

pharmadog
drugs
Brynovin

drug

patient view →

sitagliptin

Marketedupdated 2mo ago

by Revio Therapeutics LLP

Approved

community read0 votes

indications

investigational

Type 2 DiabetesDuchenne Muscular Dystrophy

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Brynovin

generic

sitagliptin

indication

Duchenne Muscular Dystrophy

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 32m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Feb 25, 2035

~8.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (5)

Oct 23, 2040formulationUS 11944621
Oct 23, 2040formulationUS 12295953
Feb 25, 2035formulationUS 10925871
Feb 25, 2035formulationUS 10925871
Feb 25, 2035formulationUS 10925871

🐶 often sniffed alongside

top 8

tagApproval8 co-mentions · 4 sources
tagSmall Molecule4 co-mentions · 4 sources
drugSITAGLIPTIN AND METFORMIN HYDROCHLORIDE3 co-mentions · 1 sources
drugSITAGLIPTIN PHOSPHATE3 co-mentions · 3 sources
drugmetformin hydrochloride SR2 co-mentions · 1 sources
drugmetformin2 co-mentions · 1 sources
drugmetformin hydrochloride2 co-mentions · 1 sources
drugmetformin hydrochloride ER2 co-mentions · 1 sources

Trials studying sitagliptin

phase4Semaglutide vs Sitagliptinenrolling by invitationn=58
phase4A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetesrecruitingn=204
N/AHbA1c Variability in Type II Diabetesactive not recruitingn=150
phase4Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)completedn=39
phase1A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteerscompletedn=60
phase2Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASHcompletedn=109
phase3A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetescompletedn=1,441
phase2Polypill Versus Metformin in New Onset Type 2 Diabeteswithdrawn

more trials →